The Immunology and Immunotherapy Research Program continues to focus on bringing basic scientists and clinicians together to address issues of cancer immunotherapy. Members are involved in:
- Expand our efforts in understanding the natural and induced immune responses to cancer.
- Develop the use of CD40/TLR agonists as a cancer vaccine platform in melanoma.
- Develop T cell-based therapies for the treatment of cancer.
- Continue to build basic and clinical interest in the treatment of ovarian cancer.
- Identify critical areas in cancer immunotherapy for faculty recruitment to grow and strengthen existing programs.
- Execute and expand efforts in DC-based vaccine trials